Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Intercure Ltd (INCR)

Intercure Ltd (INCR)
1.2200 -0.0400 (-3.17%) 13:43 ET [NASDAQ]
1.2200 x 1 1.2600 x 3
Realtime by (Cboe BZX)
1.2200 x 1 1.2600 x 3
Realtime 1.2700 +0.0100 (+0.79%) 09:11 ET
Quote Overview for Wed, Apr 9th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.2200
Day High
1.2500
Open 1.2500
Previous Close 1.2600 1.2600
Volume 13,326 13,326
Avg Vol 16,845 16,845
Stochastic %K 11.34% 11.34%
Weighted Alpha -48.65 -48.65
5-Day Change -0.0901 (-6.72%) -0.0901 (-6.72%)
52-Week Range 1.1700 - 3.7200 1.1700 - 3.7200
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,422
  • Shares Outstanding, K 45,573
  • Annual Sales, $ 96,640 K
  • Annual Income, $ -16,830 K
  • EBIT $ 5 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.28
  • Price/Sales 0.81
  • Price/Cash Flow N/A
  • Price/Book 0.49

Options Overview Details

View History
  • Implied Volatility 470.09% ( +242.83%)
  • Historical Volatility 35.68%
  • IV Percentile 99%
  • IV Rank 90.99%
  • IV High 512.93% on 04/07/25
  • IV Low 37.18% on 06/10/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 2
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 290
  • Open Int (30-Day) 322

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/17
See More
  • Average Estimate 0.52
  • Number of Estimates 2
  • High Estimate 0.53
  • Low Estimate 0.51
  • Prior Year 0.61
  • Growth Rate Est. (year over year) -14.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2300 +1.63%
on 04/10/25
Period Open: 1.5899
1.6206 -22.87%
on 03/13/25
-0.3399 (-21.38%)
since 03/10/25
3-Month
1.2300 +1.63%
on 04/10/25
Period Open: 1.6750
1.7799 -29.77%
on 02/05/25
-0.4250 (-25.37%)
since 01/10/25
52-Week
1.1700 +6.84%
on 11/15/24
Period Open: 2.4500
3.7200 -66.40%
on 05/06/24
-1.2000 (-48.98%)
since 04/10/24

Most Recent Stories

More News
Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), ( “Organigram”) a leading Canadian licensed producer of cannabis and Canndoc Ltd. (“Canndoc”), a subsidiary of InterCure Ltd. (NASDAQ: INCR) (TSX:INCR.U)...

INCR.TO : N/A (N/A)
OGI : 0.9616 (+0.69%)
OGI.TO : 1.33 (-2.21%)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)
InterCure to Release its Q2 2022 Results and Hold a Conference Call

Conference call scheduled for Tuesday, August 16, 2022, at 8:30am ET...

INCR.TO : N/A (N/A)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)
InterCure Reports Record Preliminary 2022 Second Quarter Revenue – More Than Double YoY and 9% QoQ Growth

Estimated revenue reaches CAD$36 million 1(a record NIS 95 million) Anticipates continued increases in EBITDA Revenue growth expected to...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure and Cookies Launch Flagship Retail Location in Vienna, Austria

NEW YORK and TORONTO and HERZLIYA, Israel, June 21, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) ("InterCure" or the...

INCR.TO : N/A (N/A)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)
InterCure and Cookies Successfully Launch Flagship Pharmacy in Be'er Sheva, Israel

Cookies Be'er Sheva is the largest medical cannabis dedicated pharmacy in Israel...

INCR.TO : N/A (N/A)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)
InterCure Begins 2022 with Record Breaking First Quarter Financial Results

Record revenue of $341 million in the first quarter of 2022 Adjusted EBITDA2 increased almost 110% year-over-year to $8 million Net income of $6...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure to Release its Q1 2022 Results and Hold a Conference Call

Conference call scheduled for Tuesday, May 17, 2022, at 8:00am ET...

INCR.TO : N/A (N/A)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)
InterCure to Participate in Upcoming Investor Conferences in May 2022

NEW YORK, TORONTO, and HERZLIYA, Israel, May 09, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba...

INCR.TO : N/A (N/A)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)
InterCure to Participate in A.G.P.’s Spring Consumer Cannabis Conference

NEW YORK and TORONTO and HERZLIYA, Israel, May 03, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)...

INCR.TO : N/A (N/A)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)
InterCure Reports Record Breaking Q4 and 2021 Results – Exceeded Preliminary Results

Another record year with continued industry leading growth and profitability supported by focused strategy and execution Revenue growth expected to...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure Expects to Publish its full Audited Fourth Quarter and Full Year 2021 Results Prior to the TSX Closing on April 5, 2022

Delay in publication of the Audited Results due to immaterial technical audit matters The Company expects the Audited Results will not differ from...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
CORRECTING and REPLACING -- InterCure Estimates Record Fourth Quarter and Fiscal Year End 2021 Results(1)

Fourth quarter 2021 Revenue and Adjusted EBITDA2 of $33 million and $9 million, representing an increase of almost 200% and 140% YoY, respectively Record...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure Estimates Record Fourth Quarter and Fiscal Year End 2021 Results(1)

Fourth quarter 2021 Revenue and Adjusted EBITDA2 of $33 million and $9 million, representing an increase of almost 200% and 140% YoY, respectively Record...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure to Announce Q4 & Year-End 2021 Financial Results on April 4, 2022

Will release financial results for the fourth quarter of 2021 before market open on Monday, April 4, 2022 Webcast scheduled for same day at 8:30am ET ...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure and Clever Leaves Announce International Strategic Partnership

Leading Global Cannabis Companies InterCure and Clever Leaves partner together to cultivate, market and distribute Pharmaceutical-Grade Medical Cannabis in...

CLVR : 0.0002 (unch)
CLVRW : 0.0150 (-40.00%)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)
InterCure to Participate in ROTH Capital’s 34th Annual Conference

Mr. Rabinovitch is one of the global cannabis senior executives to participate...

INCR.TO : N/A (N/A)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)
InterCure Announces Partnership with Altman Health

The partnership will focus on the new CBD wellness market in Israel Israeli Minister of Health announced yesterday that CBD will be removed from...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure Signs Definitive Agreement to Acquire Multi-National Medical Cannabis Producer “Better”

Marking the First Major Consolidation in Pharmaceutical Grade Medical Cannabis Market Acquisition is Expected to be Accretive Strengthen InterCure’s...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure Reports Record Preliminary 2021 Fourth Quarter Revenue - 3 Times YoY and 24% QoQ Growth

Estimated revenue reaches over CAD$31 million (a record NIS 77 million) Anticipates continued increases in adjusted operating profit and EBITDA ...

INCR.TO : N/A (N/A)
INCR : 1.2200 (-3.17%)
INCR-U.TO : 1.53 (+4.08%)
InterCure Announces European Expansion with International Cannabis Brand Cookies

Leading Global Cannabis Company InterCure Partners with Cookies to Open Retail Locations in Austria and the U.K. in Early 2022...

INCR.TO : N/A (N/A)
INCR-U.TO : 1.53 (+4.08%)
INCR : 1.2200 (-3.17%)

Business Summary

InterCure is a cannabis company. It is a licensed cannabis producer which offer good manufacturing practices certified and pharmaceutical-grade medical cannabis products. InterCure is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 1.3500
2nd Resistance Point 1.3200
1st Resistance Point 1.2900
Last Price 1.2200
1st Support Level 1.2300
2nd Support Level 1.2000
3rd Support Level 1.1700

See More

52-Week High 3.7200
Fibonacci 61.8% 2.7459
Fibonacci 50% 2.4450
Fibonacci 38.2% 2.1441
Last Price 1.2200
52-Week Low 1.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.